By Josh Beckerman

Merck & Co.'s (MRK) cancer drug Keytruda didn't meet its co-primary endpoints in a Phase 3 trial for treatment of patients with advanced hepatocellular carcinoma.

"While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings" from a Phase 2 study, Merck said.

Results will be presented at an upcoming medical meeting and have been shared with the U.S. Food and Drug Administration.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 19, 2019 16:38 ET (21:38 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Merck Charts.